Asabys Partners Leads a €14 Million Round in Gradient Denervation

Asabys Partners, a venture capital manager specializing in life sciences has led a financing round of €14 million in the French company Gradient Denervation Technologies, which develops an innovative solution based on catheters for the treatment of pulmonary hypertension.

Thanks to the resources obtained, the French company will be able to advance the clinical development of its minimally invasive ultrasound-based catheter for the treatment of pulmonary hypertension.

Asabys Partners leads the round through its new Sabadell Asabys II fund, but Thuja Capital and founding investor Sofinnova Partners have also participated. Gradient Denervation Technologies already secured €3.5 million from Sofinnova Partners in 2020.

Read more on the subject and find the most important business news from around the world with the Born2Invest mobile app.

Asabys Partners has invested together with Thuja Capital and Sofinnova Partners

Based in Paris, Gradient Denervation Technologies is based on innovations developed by physicians Swaminadhan Gnanashanmugam and Deffrey Feinstein at the Stanford Biodesign Program. The company started a first-in-human clinical study earlier this year.

Gradient Denervation Technologies’ new technology aims to treat patients by reducing sympathetic input into the pulmonary vasculature. The company’s initial focus is the Group 2 pulmonary hypertension population, who have heart failure and associated high pulmonary vascular resistance. 

Up to 50% of heart failure patients suffer from this debilitating condition, resulting in a large population without approved therapies. Gradient’s minimally invasive device, designed for use in the pulmonary arteries, harnesses the therapeutic energy of ultrasound to perform the denervation procedure.

Asabys Partners has nearly €217 million in assets under management

Sylvain Sachot, partner at Asabys Partners, says: “Gradient’s technology has the potential to become a first-class treatment for patients suffering from heart failure and elevated pulmonary pressures; “The company is ready to prove the concept of its technology in the clinic and we look forward to joining management on this exciting journey.”

Asabys Partners is a venture capital firm specializing in the healthcare sector, founded in 2018 by Josep Lluis Sanfeliu and Clara Campàs, owned by Alantra and with the support of Banc Sabadell as an anchor investor. With nearly €217 million in assets under management and fifteen companies in its portfolio, Asabys invests in highly innovative and disruptive companies that cover unmet medical needs in the biopharmaceutical and health technology sectors. 

__

(Featured image by Towfiqu barbhuiya via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.